Tempus AI, Inc. Share Price & Technical Analysis
TEM · $46.74 (+1.21%)
Healthcare / Health Information Services
$46.74
+1.21%
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostic…
Price chart
Seasonality
May has 1 positive and 1 negative years (last 3 years shown)
-16% return in May, 3% avg return in past 3 year May month.
-18% return in 2026, 48% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | -10% | -11% | 20% | -16% | – | – | – | – | – | – | – | -18% |
| 25 | 69% | 5% | -16% | 7% | 3% | 15% | -9% | 38% | 10% | 11% | -13% | -22% | 96% |
| 24 | – | – | – | – | – | -12% | 17% | 32% | -4% | -21% | 37% | -48% | 0% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$8.27B
P/E ratio
—
52W high
$104.3
52W low
$41.73
Volume
37,73,457
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tempus AI, Inc. share price today?
- Tempus AI, Inc. (TEM) last traded around $46.74 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TEM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TEM. Download the app for real-time alerts.
- How can I analyze Tempus AI, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.